From mass-producing insulin to building pharmaceutical AI “factories,” Lilly’s 150-year North Star remains the same: being in ...

Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Eli Lilly is a leader in one of today’s biggest growth markets: weight loss drugs. The company recently won approval for an ...

Increased full-year 2026 revenue guidance by $2 billion to a range of $82 billion to $85 billion, reflecting sustained ...

Eli Lilly and Company (NYSE:LLY) is one of the best drug stocks to buy according to analysts. Eli Lilly and Company (NYSE:LLY ...

Eli Lilly (NYSE:LLY) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on ...

The $63-billion GLP-1 agonist industry is forecast to triple in the coming decade, so it's no surprise that pharmaceuticals ...

The company still has a strong lead in its core therapeutic area.

Eli Lilly and Co. is taking another step to bolster its genetic medicine portfolio, this time through a $2.25 billion deal ...

Eli Lilly and Co. announced Tuesday that it will spend up to $7.8 billion to acquire an England-based pharmaceutical company focused on developing treatments for narcolepsy as the drugmaker continues ...

After just a few weeks on the market, thousands are already on Foundayo, Eli Lilly's oral weight loss pill. The drugmaker is ...

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the ...